A Study to Evaluate the Dose Response Based on the Efficacy, Safety &

See also
Status	Clinical Trial	Phase
Completed	`NCT04152759` - Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects	Phase 1
Completed	`NCT03248518` - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases	N/A
Completed	`NCT01925768` - Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis	Phase 3
Completed	`NCT01892436` - Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis	Phase 3
Completed	`NCT01212770` - PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis	Phase 3
Completed	`NCT05051943` - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed	`NCT01212757` - PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis	Phase 3
Completed	`NCT03953378` - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
Recruiting	`NCT02572700` - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Completed	`NCT02556034` - Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Completed	`NCT02154425` - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers	Phase 1
Completed	`NCT02188654` - Metformin in Psoriatic Arthritis	N/A
Completed	`NCT02164214` - Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?	Phase 3
Completed	`NCT01392326` - Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)	Phase 3
Completed	`NCT01083693` - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs	N/A
Not yet recruiting	`NCT00517101` - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy	N/A
Completed	`NCT00133315` - TNFalfa Blocking Treatment of Spondylarthropathies	Phase 4
Completed	`NCT00659412` - A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis	Phase 2
Completed	`NCT00946686` - To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions	Phase 1
Not yet recruiting	`NCT06059430` - Cohort Project of Patients With Inflammatory Rheumatism

NCT number	NCT02969525
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 2
Start date	October 2016
Completion date	July 2018

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis — BE ACTIVE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms